Warnings and Precautions Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...
FOR THE SEVERE DIARRHEA AND FLUSHING ASSOCIATED WITH METASTATIC CARCINOID TUMORS,
THE ONLY SSA WITH MULTIPLE DOSING OPTIONS
Multiple dosing options can help effectively manage patients' symptoms1
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is available in 10 mg, 20 mg, and 30 mg for up or down dose titration. Doses higher than 30 mg are not recommended.
Sandostatin® (octreotide acetate) Immediate-Release Injection is available for treatment initiation and symptom flare-ups
Sandostatin LAR Depot should be administered by a trained health care provider. It is important to closely follow the mixing instructions included in the packaging. Sandostatin LAR Depot must be administered immediately after mixing.
For more information about dosing, watch the video.
For Patients not currently receiving octreotide acetate
Begin therapy with Sandostatin Immediate-Release Injection.
|For carcinoid tumors:||Suggested daily dosage ranges from 100 mcg/d to 600 mcg/d in 2 to 4 divided doses (mean daily dosage is 300 mcg/d) during the first 2 weeks of therapy
|For VIPomas:||Suggested daily dose is 200 mcg to 300 mcg in 2 to 4 divided doses (range, 150 mcg - 750 mcg)
Continue Sandostatin Immediate-Release Injection for at least 2 weeks
Patients who are considered "responders" to octreotide acetate and who tolerate the drug may be switched to Sandostatin LAR Depot according to the dosage regimen described below.
Patients currently receiving Sandostatin Immediate-release Injection
Patients who are already controlled with Sandostatin Immediate-Release Injection should add Sandostatin LAR Depot according to the dosing regimen described below.
|After 2 months, consider dose adjustment||
Expect periodic symptom exacerbation
Dosing for special populations
|Renal Failure||In patients with renal failure requiring dialysis, the starting dosage should be 10 mg every 4 weeks. In other patients with renal impairment, the starting dosage should be similar to that of a patient without renal failure (ie, 20 mg every 4 weeks)|
|Hepatic Impairment—Patients With Cirrhosis||In patients with established cirrhosis of the liver, the starting dosage should be 10 mg every 4 weeks|
VIPoma(s), vasoactive intestinal peptide tumor(s).
For patients with carcinoid tumors, starting dosages of Sandostatin Immediate-Release Injection range from 100 mcg/d to 600 mcg/d in 2 to 4 divided doses. For patients with VIPomas, starting dosages range from 200 mcg/d to 300 mcg/d in 2 to 4 divided doses. Read the full Prescribing Information for Sandostatin LAR Depot.
To assess therapeutic efficacy and safety of treatment, continued patient monitoring is necessary.
Cholelithiasis and Gallbladder Sludge
Hyperglycemia and Hypoglycemia
Monitoring: Laboratory Tests
5-HIAA, 5-hydroxyindoleacetic acid.
See the proper mixing and administration of Sandostatin LAR Depot in this video.
Injection should be administered by a health care professional immediately after it is mixed.
Successful preparation and administration of Sandostatin LAR Depot relies on proper adherence to the steps below. Not following these steps can result in failure to appropriately deliver the drug.2
Schedule an in-office demonstration on mixing and administration.
If you still have questions about preparation and/or administration of Sandostatin LAR Depot, please call 1-888-NOW-NOVA (1-888-669-6682).
†For prolonged storage, Sandostatin LAR Depot should be stored at refrigerated temperatures between 2°C to 8°C (36°F to 46°F) and protected from light until the time of use.1
References: 1. Sandostatin LAR Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019. 2. Instruction Booklet: Preparation and Administration of Sandostatin LAR Depot (octreotide acetate for injectable suspension). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Please see full Prescribing Information.
Indications and Usage
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.